(2-三氟甲基苯甲酰)乙酸乙酯 | 89424-17-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (2-三氟甲基苯甲酰)乙酸乙酯
• 中文别名: 3-羰基-3-(2-三氟甲基苯基)丙酸乙基酯
• 英文名称: ethyl (2-trifluoromethylbenzoyl)acetate
• 英文别名: ethyl 3-oxo-3-(2-(trifluoromethyl)phenyl)propanoate；methyl 2-trifluoromethylbenzoylacetate；3-oxo-3-(2-trifluoromethyl-phenyl)-propionic acid ethyl ester；Ethyl 3-oxo-3-[2-(trifluoromethyl)phenyl]propanoate
• CAS: 89424-17-9
• 化学式: C₁₂H₁₁F₃O₃
• mdl: MFCD03424820
• 分子量: 260.213
• InChiKey: KMPAHDWULITWIH-UHFFFAOYSA-N

物化性质

• 沸点：
  237-238 °C (lit.)
• 密度：
  1.258 g/mL at 25 °C (lit.)
• 闪点：
  >230 °F

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2918300090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  (2-三氟甲基苯甲酰)乙酸乙酯 在 碘苯二乙酸 作用下， 以 顺-1,2-二氯乙烯 、 乙醚 、 乙醇 、 甲苯 为溶剂， 反应 5.25h， 生成 ethyl 1-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylate
  参考文献：
  名称：

  用于喹诺酮支架合成的无金属高价碘促进串联羰基迁移和未活化的 C(Ph)–C(Alkyl) 键断裂

  摘要：

  描述了一种出人意料的碘（III）介导的 3-（甲基氨基）-2-（2-取代苯甲酰基）丙烯酸酯的 C（sp 3）-C（sp 2）键断裂，用于有效合成特权支架 4-喹诺酮类药物。值得注意的是，广泛的烷基（例如甲基、叔丁基或烷基链）可以在该系统中方便地裂解。详细的机制研究表明，转化通过级联同环化和 1,2-羰基迁移进行，较小的键能通过烯胺自由基中间体决定邻位C-C 键断裂而不是 C-H 键断裂。

  DOI：

  10.1039/d2cc02245a
• 作为产物：
  描述：

  邻三氟甲基苯甲酸 在 三乙胺 、 magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 (2-三氟甲基苯甲酰)乙酸乙酯
  参考文献：
  名称：

  Synthesis of Dithiolethiones and Identification of Potential Neuroprotective Agents via Activation of Nrf2-Driven Antioxidant Enzymes

  摘要：

  Oxidative stress is implicated in the pathogenesis of a wide variety of neurodegenerative disorders, and accordingly, dietary supplement of exogenous antioxidants or/and upregulation of the endogenous antioxidant defense system are promising for therapeutic intervention or chemoprevention of neurodegenerative diseases. Nrf2, a master regulator of the cellular antioxidant machinery, cardinally participates in the transcription of cytoprotective genes against oxidative/electrophilic stresses. Herein, we report the synthesis of 59 structurally diverse dithiolethiones and evaluation of their neuroprotection against 6-hydroxydopamine- or H2O2 -induced oxidative damages in PC12 cells, a neuron-like rat pheochromocytoma cell line. Initial screening identified compounds 10 and 11 having low cytotoxicity but conferring remarkable protection on PC12 cells from oxidative-mediated damages. Further studies demonstrated that both compounds upregulated a battery of antioxidant genes as well as corresponding genes' products. Significantly, silence of Nrf2 expression abolishes cytoprotection of 10 and 11, indicating targeting Nrf2 activation is pivotal for their cellular functions. Taken together, the two lead compounds discovered here with potent neuroprotective functions against oxidative stress via Nrf2 activation merit further development as therapeutic or chemopreventive candidates for neurodegenerative disorders.

  DOI：

  10.1021/acs.jafc.9b06360

文献信息

• Improved synthesis of sterically encumbered heteroaromatic biaryls from aromatic β-keto esters
  作者：Brandon R. Rosen、Ehesan Ul Sharif、Dillon H. Miles、Nicholas S. Chan、Manmohan R. Leleti、Jay P. Powers

  DOI：10.1016/j.tetlet.2020.151855

  日期：2020.5

  A protocol for the synthesis of hindered 4-aryl 2-aminopyrimidines from β–keto esters is described. The process employs trifluoroethanol as an essential additive to promote the guanidine condensation reaction, enabling the synthesis of 25 aryl- and heteroaryl substituted aminopyrimidines in good yields and high purities with no column chromatography. The conditions described herein are readily scalable

  描述了由β-酮酸酯合成受阻4-芳基2-氨基嘧啶的方法。该方法采用三氟乙醇作为促进胍缩合反应的必要添加剂，无需柱色谱法即可以高收率和高纯度合成25个芳基和杂芳基取代的氨基嘧啶。本文所述的条件易于扩展，并且已用于临床A 2a / A 2b R拮抗剂AB928的大规模合成。
• [EN] PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS INHIBITEURS DE JAK À LA PYRAZOLOPYRIMIDINE ET PROCÉDÉS
  申请人：GENENTECH INC

  公开号：WO2010051549A1

  公开（公告）日：2010-05-06

  The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient. Ia

  这项发明提供了Formula Ia的JAK激酶抑制剂，其对映体、二对映体或其药学上可接受的盐，其中R1、R2、R7和Z在此处被定义，包括Formula Ia化合物和药学上可接受的载体、辅料或载体的药物组合物，以及治疗或减轻对JAK激酶活性抑制有响应的疾病或病况的方法。
• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Blaney Jeffrey

  公开号：US20120022043A1

  公开（公告）日：2012-01-26

  The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

  该发明提供了Formula Ia的JAK激酶抑制剂，其对映体、二对映体或其药学上可接受的盐，其中R1、R2、R7和Z在此处定义，包括Formula Ia化合物和药学上可接受的载体、辅料或载体的药物组合物，以及治疗或减轻对JAK激酶活性抑制有响应的疾病或病况的方法。
• A One-Pot Copper(II)-Catalyzed Tandem Synthesis of 2-Substituted Pyrrolo[1,2-<i>b</i>]pyridazin-4(1<i>H</i>)-ones
  作者：Cun Tan、Haoyue Xiang、Qian He、Chunhao Yang

  DOI：10.1002/ejoc.201500422

  日期：2015.6

  A one-pot copper(II)-catalyzed tandem synthesis of 2-substituted pyrrolo[1,2-b]pyridazin-4(1H)-ones from N-aminopyrroles was developed. This tandem reaction involves a Conrad–Limpach-type reaction, including the thermal condensation of N-aminopyrroles with the carbonyl group of β-oxo esters followed by the cyclization of Schiff base intermediates. Compared to the traditional Conrad–Limpach quinoline

  开发了一种一锅铜 (II) 催化串联合成 2-取代的吡咯并 [1,2-b] 哒嗪-4(1H)-酮从 N-氨基吡咯。这种串联反应涉及 Conrad-Limpach 型反应，包括 N-氨基吡咯与 β-氧代酯的羰基的热缩合，然后是席夫碱中间体的环化。与传统的 Conrad-Limpach 喹啉合成相比，我们在此首次成功地将铜 (II) 作为催化剂应用于该转化中，以提供 2-取代的吡咯并[1,2-b]哒嗪-4(1H)-酮。大多数带有给电子 (EDG) 和吸电子 (EWG) 基团的基材都适用于该程序。相应的产品可以直接转化为多种吡咯并[1,2-b]哒嗪用于药物发现和材料科学。
• SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1
  申请人：Bartberger D. Michael

  公开号：US20080021022A1

  公开（公告）日：2008-01-24

  Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorder: wherein the variables A-B, R 1 , R 2 , m, and Q are described herein.

  化合物的公式I和IV已经描述，并具有治疗效用，特别是在治疗糖尿病、肥胖和相关疾病和紊乱方面： 其中变量A-B、R1、R2、m和Q在此处描述。